Evidence map›Paper›PMID 32359702›Full record

ArticleEuropean urology2020

Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.

Luca Afferi, Marco Moschini, Agostino Mattei, Francesco Montorsi, Alberto Briganti, Xavier Cathelineau, Rafael Sanchez-Salas

Abstract readComment
PubMed Publisher
In one paragraph

Article in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Luca AfferiDepartment of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
Marco MoschiniDepartment of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
Agostino MatteiDepartment of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.
Francesco MontorsiDepartment of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
Alberto BrigantiDepartment of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
Xavier CathelineauDepartment of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.
Rafael Sanchez-SalasDepartment of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France. Electronic address: rafael.sanchez-salas@imm.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Transitional CellUrologic NeoplasmsChemotherapy, AdjuvantHumans

Identifiers

PMID32359702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.